Valeant (VRX) Could Take a Large Write Down on Sprout - Wells Fargo's Maris
Get Alerts VRX Hot Sheet
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 7 | New: 39
Join SI Premium – FREE
Wells Fargo analyst David Maris sees Valeant Pharmaceuticals (NYSE: VRX) taking a large impairment charge on the carrying value of Sprout.
The charge could be as much 90% of its value, or more, Maris said, and without the addback to adjusted earnings going forward, this write-off would be a $0.14 per share headwind to annual adjusted EPS in 2017E and beyond.
"We believe there may be other assets that face this same problem, compounding Valeant’s divestiture plans, as Valeant would lose not only the cash flow from the products, but the addback to adjusted EPS of potentially overstated intangible asset amortization," he added.
The firm maintained their Underperform rating and $17-$22 valuation range.
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $26.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Downgrades Nuscale Power (SMR) to Underweight, 'Behind the Eight Ball'
- Hannover Rueck SE (HNR1:GR) (HVRRF) PT Raised to EUR290 at JPMorgan, 'Updating estimates'
- Mizuho Starts Lowe's (LOW) at Buy, 'Bringing the Lumber as Headwinds Abate, With or Without the Fed'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Hot Comments, Short Sales, Trader TalkRelated Entities
Earnings, Wells Fargo, David MarisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!